Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the ...

Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the ...

Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the ...

Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended ...

Puma in-licenses the global development and commercialization rights to PB272 — neratinib, oral; PB272 — neratinib, intravenous; and PB357. Neratinib, oral was approved by the U.S. Food and ...

Puma Biotechnology, known for its development and commercialization of NERLYNX® (neratinib) tablets, has been expanding its portfolio. NERLYNX® is approved in the U.S. for certain types of early ...

There is currently an ongoing Phase 1 trial that is sponsored by the National Cancer Institute to evaluate the combination of neratinib and trastuzumab deruxtecan, otherwise known as in HER2 in ...